TERN-101 demonstrated a favorable safety profile and improved ALT levels and liver steatosis in the phase 2a LIFT RCT in patients with pre-cirrhotic NASH [67]. The gene discussed is GPT; the disease is metabolic dysfunction-associated steatohepatitis.